title: Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.
abstract: BACKGROUND
  Appendiceal mucinous neoplasms present, in most patients, with peritoneal dissemination at the time of initial diagnosis. Patients may have a borderline tumor showing disseminated peritoneal adenomucinosis or an aggressive malignancy identified as peritoneal mucinous adenocarcinoma. Patients with these diagnoses were treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  
  
  METHODS
  A database was established in 1998 that prospectively evaluated the morbidity and mortality of this group of patients. By using common toxicity grading criteria, 8 categories were scored on a grade of I to V. Grade IV indicated that the adverse event required urgent and definitive intervention: often a return to the operating room or to the surgical intensive care unit. Grade V indicated that the adverse events resulted in the patient's death. Adverse events were tabulated for each cytoreduction performed in these appendiceal malignancy patients.
  
  
  RESULTS
  There were 356 procedures in patients taken to the operating room who received cytoreductive surgery with peritonectomy procedures plus heated intraoperative intraperitoneal chemotherapy. Only patients who had this combined treatment at our institution were included in the analysis. The total 30-day or in-hospital mortality was 2.0%. Nineteen percent of procedures were accompanied by at least one grade IV adverse event, and 11.1% of patients returned to the operating room. The most common category of grade IV complications was hematological (28%), followed by gastrointestinal (26%).
  
  
  CONCLUSIONS
  The mortality of 2.0% and the overall grade IV morbidity of 19% in these patients may be acceptable in light of modern standards for the management of gastrointestinal cancer.
authors.affiliation: Washington Cancer Institute, 106 Irving Street, N.W., Suite 3900, Washington, DC 20010, USA. paul.sugarbaker@medstar.net
authors.forename: Paul H
authors.initials: PH
authors.lastname: Sugarbaker
authors.forename: Robert
authors.initials: R
authors.lastname: Alderman
authors.forename: Gary
authors.initials: G
authors.lastname: Edwards
authors.forename: Christina Ellen
authors.initials: CE
authors.lastname: Marquardt
authors.forename: Vadim
authors.initials: V
authors.lastname: Gushchin
authors.forename: Jesus
authors.initials: J
authors.lastname: Esquivel
authors.forename: David
authors.initials: D
authors.lastname: Chang
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001063:Appendiceal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D018579:Patient Selection; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D011379:Prognosis; D011446:Prospective Studies; D012086:Reoperation; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D005472:Fluorouracil